Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis

Abstract Disease progression of myeloproliferative neoplasms is the result of increased genomic complexity. Since the ability to predict disease evolution is crucial for clinical decisions, we studied single-cell genomics and transcriptomics of CD34-positive cells from a primary myelofibrosis (PMF)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sandra Parenti, Sebastiano Rontauroli, Chiara Carretta, Selene Mallia, Elena Genovese, Chiara Chiereghin, Clelia Peano, Lara Tavernari, Elisa Bianchi, Sebastian Fantini, Stefano Sartini, Oriana Romano, Silvio Bicciato, Enrico Tagliafico, Matteo Della Porta, Rossella Manfredini
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/644d99d3c3d744418f3c13018b7b3bc7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:644d99d3c3d744418f3c13018b7b3bc7
record_format dspace
spelling oai:doaj.org-article:644d99d3c3d744418f3c13018b7b3bc72021-12-02T14:40:00ZMutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis10.1038/s41698-021-00144-92397-768Xhttps://doaj.org/article/644d99d3c3d744418f3c13018b7b3bc72021-02-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00144-9https://doaj.org/toc/2397-768XAbstract Disease progression of myeloproliferative neoplasms is the result of increased genomic complexity. Since the ability to predict disease evolution is crucial for clinical decisions, we studied single-cell genomics and transcriptomics of CD34-positive cells from a primary myelofibrosis (PMF) patient who progressed to acute myeloid leukemia (AML) while receiving Ruxolitinib. Single-cell genomics allowed the reconstruction of clonal hierarchy and demonstrated that TET2 was the first mutated gene while FLT3 was the last one. Disease evolution was accompanied by increased clonal heterogeneity and mutational rate, but clones carrying TP53 and FLT3 mutations were already present in the chronic phase. Single-cell transcriptomics unraveled repression of interferon signaling suggesting an immunosuppressive effect exerted by Ruxolitinib. Moreover, AML transformation was associated with a differentiative block and immune escape. These results suggest that single-cell analysis can unmask tumor heterogeneity and provide meaningful insights about PMF progression that might guide personalized therapy.Sandra ParentiSebastiano RontauroliChiara CarrettaSelene MalliaElena GenoveseChiara ChiereghinClelia PeanoLara TavernariElisa BianchiSebastian FantiniStefano SartiniOriana RomanoSilvio BicciatoEnrico TagliaficoMatteo Della PortaRossella ManfrediniNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Sandra Parenti
Sebastiano Rontauroli
Chiara Carretta
Selene Mallia
Elena Genovese
Chiara Chiereghin
Clelia Peano
Lara Tavernari
Elisa Bianchi
Sebastian Fantini
Stefano Sartini
Oriana Romano
Silvio Bicciato
Enrico Tagliafico
Matteo Della Porta
Rossella Manfredini
Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
description Abstract Disease progression of myeloproliferative neoplasms is the result of increased genomic complexity. Since the ability to predict disease evolution is crucial for clinical decisions, we studied single-cell genomics and transcriptomics of CD34-positive cells from a primary myelofibrosis (PMF) patient who progressed to acute myeloid leukemia (AML) while receiving Ruxolitinib. Single-cell genomics allowed the reconstruction of clonal hierarchy and demonstrated that TET2 was the first mutated gene while FLT3 was the last one. Disease evolution was accompanied by increased clonal heterogeneity and mutational rate, but clones carrying TP53 and FLT3 mutations were already present in the chronic phase. Single-cell transcriptomics unraveled repression of interferon signaling suggesting an immunosuppressive effect exerted by Ruxolitinib. Moreover, AML transformation was associated with a differentiative block and immune escape. These results suggest that single-cell analysis can unmask tumor heterogeneity and provide meaningful insights about PMF progression that might guide personalized therapy.
format article
author Sandra Parenti
Sebastiano Rontauroli
Chiara Carretta
Selene Mallia
Elena Genovese
Chiara Chiereghin
Clelia Peano
Lara Tavernari
Elisa Bianchi
Sebastian Fantini
Stefano Sartini
Oriana Romano
Silvio Bicciato
Enrico Tagliafico
Matteo Della Porta
Rossella Manfredini
author_facet Sandra Parenti
Sebastiano Rontauroli
Chiara Carretta
Selene Mallia
Elena Genovese
Chiara Chiereghin
Clelia Peano
Lara Tavernari
Elisa Bianchi
Sebastian Fantini
Stefano Sartini
Oriana Romano
Silvio Bicciato
Enrico Tagliafico
Matteo Della Porta
Rossella Manfredini
author_sort Sandra Parenti
title Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
title_short Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
title_full Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
title_fullStr Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
title_full_unstemmed Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
title_sort mutated clones driving leukemic transformation are already detectable at the single-cell level in cd34-positive cells in the chronic phase of primary myelofibrosis
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/644d99d3c3d744418f3c13018b7b3bc7
work_keys_str_mv AT sandraparenti mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT sebastianorontauroli mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT chiaracarretta mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT selenemallia mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT elenagenovese mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT chiarachiereghin mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT cleliapeano mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT laratavernari mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT elisabianchi mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT sebastianfantini mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT stefanosartini mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT orianaromano mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT silviobicciato mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT enricotagliafico mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT matteodellaporta mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
AT rossellamanfredini mutatedclonesdrivingleukemictransformationarealreadydetectableatthesinglecelllevelincd34positivecellsinthechronicphaseofprimarymyelofibrosis
_version_ 1718390417005740032